港股異動 | 康方生物-B漲超8%創新高,昨日宣佈配股淨籌11.7億港元
uSMART盈立智投1月8日消息,週五港股早盤,康方生物-B盤中漲超8%,截至10:00分,股價盤中最高觸及45.55港元創新高。
昨日,康方生物發佈公告稱,擬折讓4.6%配股,淨籌11.7億港元,將用於設立集團商業化團隊以籌備於2022年推出AK104(PD-1/CTLA-4),並繼續聘任及留任國內外市場的人才;於中國廣州及中山翠亨新區建設並發展新生產設施;爲更多的國際臨牀試驗需求提供資金;資助並加快其他臨牀項目(包括PCSK9、IL12/IL23)的發展等。
機構觀點:
大和此前發表研究報告指,康方生物旗下腫瘤免疫治療藥物AK104的數據讀數按計劃進行,主要集中在2021年1月和6月。該行將其目標價由45港元上調至60港元,維持買入評級。
大摩此前發佈報告指,康方生物藥物名單豐富及研發引擎強勁,升其目標價至43.5港元,給予增持評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.